Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accumulated Expenses (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Accumulated Expenses for 15 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 69.23% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 69.23% year-over-year, with the annual reading at $2.4 million for FY2025, 69.23% down from the prior year.
  • Accumulated Expenses hit $2.4 million in Q4 2025 for Cardiff Oncology, down from $3.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $8.9 million in Q1 2025 to a low of $2.0 million in Q3 2024.
  • Historically, Accumulated Expenses has averaged $4.8 million across 5 years, with a median of $4.6 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: surged 188.53% in 2024 and later crashed 69.23% in 2025.
  • Year by year, Accumulated Expenses stood at $4.5 million in 2021, then rose by 14.36% to $5.2 million in 2022, then crashed by 47.13% to $2.7 million in 2023, then surged by 188.53% to $7.9 million in 2024, then crashed by 69.23% to $2.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for CRDF at $2.4 million in Q4 2025, $3.1 million in Q3 2025, and $2.2 million in Q2 2025.